(116 days)
Not Found
No
The description focuses on the detection and processing of electromagnetic signals from implanted markers to determine position, without mentioning any AI or ML techniques for analysis or decision-making. The "Mentions AI, DNN, or ML" section is explicitly marked as "Not Found".
No
The device is described as an "adjunct in treatment planning and radiation therapy" to align and monitor the patient's position, providing localization and tracking information. It does not exert a therapeutic effect itself but assists in the delivery of radiation therapy.
No
This device is used for localizing and monitoring the patient's position and the treatment target during radiation therapy, not for diagnosing a medical condition. It's an adjunct tool for treatment planning and delivery.
No
The device description explicitly mentions "detection of electromagnetic signals from passive implanted markers" and "system's detection of electromagnetic signals". This indicates the device includes hardware components (sensors, receivers, etc.) to detect these signals, in addition to any software for processing and display. The performance studies also mention "electromagnetic compatibility" testing, further supporting the presence of hardware.
Based on the provided information, the Calypso 4D Localization System is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Calypso System Function: The Calypso System works by detecting electromagnetic signals from implanted markers (Beacon transponders) within the patient's body. It is used for localization and monitoring of a treatment target during radiation therapy, which is an in-vivo procedure.
- No Sample Analysis: The system does not analyze biological samples taken from the patient.
Therefore, the Calypso 4D Localization System falls under the category of a medical device used for treatment planning and delivery, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Calypso® 4D Localization System is intended for use as an adjunct in treatment planning and radiation therapy, to align and monitor the patient's position relative to the isocenter of a linear accelerator. The Calypso System provides accurate, precise, and continuous localization of a treatment isocenter by using two or more Beacon® transponders.
Beacon transponders are indicated for permanent implantation in the prostate only.
Product codes (comma separated list FDA assigned to the subject device)
IYE
Device Description
The Calypso 4D Localization System (Calypso System) is designed to provide accurate, objective, and continuous localization of a treatment target for patient alignment and target position monitoring during radiation therapy. Use of the Calypso System for target localization is based on the system's detection of electromagnetic signals from passive implanted markers, called Beacon transponders. The Beacon transponders are implanted in or near the treatment target. When used with the Calypso System, the Beacon transponder signals enable objective measurement of the location of the treatment target in 3 dimensions. The system operator uses this information to align the patient's treatment target to the isocenter of the linear accelerator prior to radiation therapy and to monitor the position of the treatment target during treatment.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
prostate
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing:
The Calypso System and Beacon transponders have been the subject of performance testing, including design verification and validation, packaging, sterility, electromagnetic compatibility as well as other assessments to demonstrate that the system meets its intended use, is safe and effective, and performs comparably to legally marketed devices. Other types of testing, such as biocompatibility and software verification and validation, also were performed.
Summary of Clinical and Nonclinical Testing:
Clinical and nonclinical testing demonstrates that the Calypso System is safe and effective, and performs comparably to legally marketed devices. The system was used successfully to localize patients during set-up and alignment and to track prostate motion during therapy delivery in a subset of the patients. Results show that the Calypso System can accurately and reliably provide localization and tracking information throughout all treatment fractions.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K983660, K003285, K040585, K960330, K983529, K994270, K012575
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
5.0 510(K) SUMMARY OF SAFETY & EFFECTIVENESS
This 510(k) Summary of Safety and Effectiveness is provided in accordance with 21 CFR 807.92.
Date of preparation: March 31, 2006
Submitter information:
Calypso® Medical Technologies, Inc. 2101 Fourth Avenue, Suite 1550 Seattle, WA 98121
Phone: 206-254-0600 Fax: 206-254-0606
Contact: Sue Ridge Regulatory Affairs/Quality Systems Manager
- Device trade name: Calypso® 4D Localization System
- Common name: Patient localization system
Classification name: Accelerator, Linear, Medical
Classification:
CFR 892.5050 Class II Product code - IYE
Predicate devices: BrainLAB ExacTrac Patient Positioning System (K983660, K003285, K040585)
GE Medical Systems Instatrak System (K960330, K983529, and K994270)
Northwest Medical Physics Equipment (NMPE) Acculoc implanted fiducials (K012575)
1
Indications for use:
The Calypso® 4D Localization System is intended for use as an adjunct in treatment planning and radiation therapy, to align and monitor the patient's position relative to the isocenter of a linear accelerator. The Calypso System provides accurate, precise, and continuous localization of a treatment isocenter by using two or more Beacon® transponders.
Beacon transponders are indicated for permanent implantation in the prostate only.
Device description:
The Calypso 4D Localization System (Calypso System) is designed to provide accurate, objective, and continuous localization of a treatment target for patient alignment and target position monitoring during radiation therapy. Use of the Calypso System for target localization is based on the system's detection of electromagnetic signals from passive implanted markers, called Beacon transponders. The Beacon transponders are implanted in or near the treatment target. When used with the Calypso System, the Beacon transponder signals enable objective measurement of the location of the treatment target in 3 dimensions. The system operator uses this information to align the patient's treatment target to the isocenter of the linear accelerator prior to radiation therapy and to monitor the position of the treatment target during treatment.
Performance testing:
The Calypso System and Beacon transponders have been the subject of performance testing, including design verification and validation, packaging, sterility, electromagnetic compatibility as well as other assessments to demonstrate that the system meets its intended use, is safe and effective, and performs comparably to legally marketed devices. Other types of testing, such as biocompatibility and software verification and validation, also were performed.
Summary of Clinical and Nonclinical Testing:
Clinical and nonclinical testing demonstrates that the Calypso System is safe and effective, and performs comparably to legally marketed devices. The system was used successfully to localize patients during set-up and alignment and to track prostate motion during therapy delivery in a subset of the patients. Results show that the Calypso System can accurately and reliably provide localization and tracking information throughout all treatment fractions.
2
Image /page/2/Picture/1 description: The image shows a logo with a circular border containing the words "HUMAN SERVICES USA" in a sans-serif font. Inside the circle is a stylized symbol consisting of three curved lines that resemble a person or figure in motion. The logo is black and white and appears to be a seal or emblem.
Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850
JUL 2 8 2006
Mr. Eric Meier President and Chief Executive Officer Calvpso Medical Technologies, Inc. 2101 Fourth Avenue, Suite 1550 SEATTLE WA 98121
Re: K060906
Trade/Device Name: Calypso 4D Localization System Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: IYE Dated: June 22, 2006 Received: June 26, 2006
Dear Mr. Meier:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Image /page/2/Picture/10 description: The image is a black and white circular logo or emblem. The text "1906-2006" is at the top of the circle. The letters "PA" are in the center of the circle in a bold font. The word "Centennial" is below the letters "PA". There are three stars below the word "Centennial".
Protecting and Promoting Public Health
3
Page 2 -
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 21 CFR 876.xxx | (Gastroenterology/Renal/Urology | 240-276-0115 |
|---|---|---|
| 21 CFR 884.xxx | (Obstetrics/Gynecology) | 240-276-0115 |
| 21 CFR 894.xxx | (Radiology) | 240-276-0120 |
| Other | 240-276-0100 |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150
or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Nancy C. Brogdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
4.0 INDICATIONS FOR USE STATEMENT
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Device Name: _____________ Calypso 4D Localization System
Indication for Use:
The Calypso® 4D Localization System is intended for use as an adjunct in treatment planning and radiation therapy, to align and monitor the patient's position relative to the isocenter of a linear accelerator. The Calypso System provides accurate, precise, and continuous localization of a treatment isocenter by using two or more Beacon® transponders.
Beacon transponders are indicated for permanent implantation in the prostate only.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-the-counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Janeye broglon
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number Ka60906
Page 4.1